Replies to post #480901 on Anavex Life Sciences Corp (AVXL)

[xodcode]

They showed their true colors by opposing Peer Review signed by 58 neurologists, including world authorities in the field,

Agreed! With EMA acceptance implying a very high probability according to ChatGPT (60% to 90%) of approval in 6 to 12 months, and supported by the JPAD publication, it appears that AVXL has first down on the opposing team's 1 yard line. Even JPMorgan opened a slot for AVXL at their annual conference.

I was particularly pleased with the JPM slide 28 showing the capsules, ready to go, emphasizing the ease of application compared to the already approved competition. Pleasing also, was Mr. Missing's comment that blarcamesine pricing discussions have/are already taking place in many countries. These are not the actions of someone who is not supremely confident in EMA approval.

Yes, AVXL price has been beaten down these past few days, but that has nothing to do with anything but the raft of call options, especially the $10Jan calls, that expired worthless. Blarcamesine has been shown conclusively to be the best alternative in the market for mitigation Alzheimer progress, and may well demonstrate conclusively in the fairly near term its prophylactic value. The naysayers and market makers have had their day and it is a matter of time now for the big boys to climb aboard the blarcamesine train.

I doubt very much that naysayers and fudsters will succeed much longer in their efforts at blemishing blarcamesine, especially given how low the bar has been set with the lecanemab and donanemab approvals. Consequently, I doubt very much that mm's will succeed in reining in AVXL price much longer. Blarcamesine will be granted approval by EMA and I doubt that AVXL price advances will wait for that EMA approval given that, as stated above, the probability of EMA success is close to 90% according to ChatGPT.